GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (XBRU:ARGX) » Definitions » Debt-to-EBITDA

argenx SE (XBRU:ARGX) Debt-to-EBITDA

: -0.08 (As of Dec. 2023)
View and export this data going back to 2014. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

argenx SE's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €4 Mil. argenx SE's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €14 Mil. argenx SE's annualized EBITDA for the quarter that ended in Dec. 2023 was €-223 Mil. argenx SE's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.08.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for argenx SE's Debt-to-EBITDA or its related term are showing as below:

XBRU:ARGX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.1   Med: -0.03   Max: -0.02
Current: -0.07

During the past 13 years, the highest Debt-to-EBITDA Ratio of argenx SE was -0.02. The lowest was -0.10. And the median was -0.03.

XBRU:ARGX's Debt-to-EBITDA is ranked worse than
100% of 278 companies
in the Biotechnology industry
Industry Median: 1.375 vs XBRU:ARGX: -0.07

argenx SE Debt-to-EBITDA Historical Data

The historical data trend for argenx SE's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.02 -0.03 -0.02 -0.10

argenx SE Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 - -0.03 - -0.08

Competitive Comparison

For the Biotechnology subindustry, argenx SE's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


argenx SE Debt-to-EBITDA Distribution

For the Biotechnology industry and Healthcare sector, argenx SE's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where argenx SE's Debt-to-EBITDA falls into.



argenx SE Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

argenx SE's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4.26 + 14.08) / -176.325
=-0.10

argenx SE's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4.26 + 14.08) / -223.38
=-0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


argenx SE  (XBRU:ARGX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


argenx SE Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of argenx SE's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


argenx SE (XBRU:ARGX) Business Description

Address
Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.